# Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobu

Source: https://onco.cc/trials/nct07387471/  
OnCo record `nct07387471` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Venetoclax in waldenström macroglobulinaemia, run by AbbVie, active and no longer recruiting.

## Summary

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) is a phase 2 interventional study registered as NCT07387471 by AbbVie, with 14 participants planned, started 2026-03-17 and due to reach its primary completion in 2028-07. Interventions recorded: Venetoclax. Conditions listed: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07387471
- Phase: 2
- Setting: A Phase 2 Study of Venetoclax Monotherapy in Japanese Subjects With Relapsed or Refractory Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Sponsor: AbbVie
- Enrolled: 14

## Sources

- ClinicalTrials.gov NCT07387471: https://clinicaltrials.gov/study/NCT07387471

## Connected records

- cancers: [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct07387471.json